Literature DB >> 14717977

Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor.

C Soulet1, V Sauzeau, M Plantavid, J M Herbert, P Pacaud, B Payrastre, P Savi.   

Abstract

The P2Y12 ADP receptor is one of the major regulators of platelet activation and the target of antithrombotic thienopyridines (ticlopidine and clopidogrel). It has been recently cloned but the signaling pathways triggered by this receptor are still poorly documented. Here, we show that stimulation of the human P2Y12 receptor stably expressed in Chinese hamster ovary cells activates two major intracellular signaling mechanisms leading either to cell proliferation or to actin cytoskeleton reorganization. Both effects were blocked by the active metabolite of clopidogrel, a specific antagonist of P2Y12. The P2Y12-mediated stimulation of proliferation required the pertussis toxin-sensitive activation of PI3-kinase/Akt upstream of MAP-kinases. A partial contribution of a transactivation mechanism, through the tyrosine kinase receptor platelet-derived growth factor (PDGF)-R-beta, was also observed. Conversely, the P2Y12-mediated reorganization of the actin cytoskeleton was Gi-independent, requiring activation of RhoA and Rho-kinase. Our results provide new insights into the molecular basis of P2Y12-mediated intracellular signaling. These data may prove to be useful for a better understanding of the physiological role of P2Y12, particularly in platelets and glial cells which express this important therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717977     DOI: 10.1111/j.1538-7836.2004.00556.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

1.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

Review 2.  P2 receptors: intracellular signaling.

Authors:  Laurie Erb; Zhongji Liao; Cheikh I Seye; Gary A Weisman
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

Review 3.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 4.  Interaction of P2 purinergic receptors with cellular macromolecules.

Authors:  Laszlo Köles; Zoltan Gerevich; João Felipe Oliveira; Zoltan Sandor Zadori; Kerstin Wirkner; Peter Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 5.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

6.  Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors.

Authors:  Liaman K Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2006-08-28       Impact factor: 5.858

7.  P2Y12 receptor expression is a critical determinant of functional responsiveness to ATX's MORFO domain.

Authors:  Jameel Dennis; Magdalena K Morgan; Martin R Graf; Babette Fuss
Journal:  Purinergic Signal       Date:  2011-12-04       Impact factor: 3.765

8.  Coupling of P2Y receptors to G proteins and other signaling pathways.

Authors:  Laurie Erb; Gary A Weisman
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012 Nov-Dec

Review 9.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

10.  Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.

Authors:  Riyaad Aungraheeta; Alexandra Conibear; Mark Butler; Eamonn Kelly; Sven Nylander; Andrew Mumford; Stuart J Mundell
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.